Eicosapentaenoic acid attenuates hyperoxia-induced lung injury via p38 MAPK/NF-κB-mediated regulation of glycolytic reprogramming
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2025.115903 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Suheng Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu 730000, China. Hauptthemen laut MEDLINE: Eicosapentaenoic Acid, Hyperoxia, Lung Injury, Anti-Inflammatory Agents. Die Arbeit nennt 65 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Despite being a lifesaving intervention for many conditions, supplemental oxygen therapy carries the risk of severe hyperoxia-induced lung injury (HLI). The lack of effective countermeasures drives the urgent need for novel therapeutic strategies and mechanistic research to improve clinical outcomes. Eicosapentaenoic acid (EPA), a marine-derived polyunsaturated fatty acid with anti-inflammatory, antioxidant, and immunomodulatory properties, has exhibited lung-protective effects in experimental models of chronic obstructive pulmonary disease and bronchial asthma, suggesting its potential clinical value. However, its effects on HLI remain unexplored. This study investigated the therapeutic potential of EPA in alleviating HLI and elucidated its underlying mechanisms. We established both cellular and animal models of HLI; using these models, we integrated network pharmacology analysis to evaluate the efficacy of EPA and explore its potential mechanisms of action. Results demonstrated that EPA significantly ameliorated hyperoxia-induced oxidative stress, inflammatory responses, glycolytic reprogramming, and apoptosis in BEAS-2B and MLE-12 cells in vitro. Network pharmacology analysis revealed that EPA likely targets the MAPK/NF-κB signaling pathway. Western blotting and immunofluorescence confirmed that EPA attenuated hyperoxia-induced cellular damage by inhibiting p38 MAPK phosphorylation and reducing NF-κB nuclear translocation. In vivo, EPA suppressed the p38 MAPK/NF-κB signaling pathway, reduced inflammation and metabolic reprogramming in lung tissue, and thereby alleviated hyperoxia-induced pathological damage. This study substantiates that EPA ameliorates HLI by modulating glycolytic reprogramming via the p38 MAPK/NF-κB signaling pathway in vitro and in vivo, thereby providing a potential therapeutic strategy and laying the groundwork for its clinical application in HLI management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu 730000, China.
- Department of Anesthesiology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, China.
- Department of Anesthesiology, Peking University Cancer Hospital Inner Mongolia, Hohhot, Inner Mongolia 010000, China.
- The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu 730000, China; Department of Anesthesiology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, China. Electronic address: liyul@lz…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, S., Gan, L., Qu, S., Yu, K., Guo, H., Lai, R., Cui, J., & Li, Y. (2026). Eicosapentaenoic acid attenuates hyperoxia-induced lung injury via p38 MAPK/NF-κB-mediated regulation of glycolytic reprogramming. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115903
Vancouver
Chen S, Gan L, Qu S, Yu K, Guo H, Lai R, et al. Eicosapentaenoic acid attenuates hyperoxia-induced lung injury via p38 MAPK/NF-κB-mediated regulation of glycolytic reprogramming. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2025.115903
BibTeX
@article{Chen2026,
author = {Chen, Suheng and Gan, Lu and Qu, Shanshan and Yu, Kaihua and Guo, Hong and Lai, Ruiyin and Cui, Junjie and Li, Yulan},
title = {Eicosapentaenoic acid attenuates hyperoxia-induced lung injury via p38 MAPK/NF-κB-mediated regulation of glycolytic reprogramming},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2025.115903}
}
EUVIMED